STAMFORD, Conn., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists' annual meeting, to be held October 21-25, 2017 in Boston.
Presentations will include clinical trial data for CR845, Cara's first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentations are as follows:
|CR845 Oral Abstract Presentation: |
| || |
|Title: ||"Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid
|Abstract Number: ||JS01|
|Date / Time: ||Sunday, October 22, 2017; 9:00 a.m. - 12:00 p.m. ET |
|Presenter:||Eugene Viscusi, M.D., Director, Acute Pain Management, Thomas Jefferson University|
| || |
| || |
|Title: ||"A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)"|
|Date / Time: ||Sunday, October 22, 2017; 7:00 - 8:00 a.m. ET|
|Presenters:||Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics|
| ||Christopher L. Wu, M.D., Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital|
For information about ANESTHESIOLOGY® 2017, visit www.asahq.org/annualmeeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the
undesirable side effects typically associated with currently available opioid pain therapeutics.
Stern Investor Relations, Inc.
Source: Cara Therapeutics, Inc.
News Provided by Acquire Media